Skip to main content Back to Top
Advertisement

9/27/2016

Cefpodoxime

Products Affected - Description

    • Cefpodoxime oral suspension, Aurobindo, 100 mg/5 mL, 100 mL bottle, 1 count, NDC 65862-0141-01
    • Cefpodoxime oral suspension, Aurobindo, 100 mg/5 mL, 50 mL bottle, 1 count, NDC 65862-0141-50
    • Cefpodoxime oral suspension, Aurobindo, 50 mg/5 mL, 100 mL bottle, 1 count, NDC 65862-0140-01
    • Cefpodoxime oral suspension, Aurobindo, 50 mg/5 mL, 50 mL bottle, 1 count, NDC 65862-0140-50
    • Cefpodoxime oral suspension, Sandoz, 100 mg/5 mL, 50 mL bottle, 1 count, NDC 00781-6169-52
    • Cefpodoxime oral suspension, Sandoz, 50 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6168-46
    • Cefpodoxime oral suspension, Sandoz, 50 mg/5 mL, 50 mL bottle, 1 count, NDC 00781-6168-52

Reason for the Shortage

    • Aurobindo discontinued cefpodoxime oral suspension.
    • Pfizer has discontinued Vantin.
    • Ranbaxy has an import ban on all solid medications including cefpodoxime.
    • Sandoz could not provide a reason for the shortage. They have discontinued 50 mg/mL 50 mL and 100 mL oral suspension and 100 mg/mL 50 mL oral suspension.

Available Products

    • Cefpodoxime oral tablet, Aurobindo, 100 mg, 20 count, NDC 65862-0095-20
    • Cefpodoxime oral tablet, Aurobindo, 200 mg, 20 count, NDC 65862-0096-20
    • Cefpodoxime oral suspension, Sandoz, 100 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6169-46
    • Cefpodoxime oral tablet, Sandoz, 100 mg, 20 count, NDC 00781-5438-20
    • Cefpodoxime oral tablet, Sandoz, 200 mg, 20 count, NDC 00781-5439-20
    • Cefpodoxime oral tablet, Sandoz, 200 mg, 100 count, NDC 00781-5439-01

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated September 27, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 20, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins